STELLAR PHARMACEUTICALS ANNOUNCES 2005 SECOND QUARTER FINANCIAL RESULTS

Stellar Pharmaceuticals Inc. ("Stellar") (OTCBB:SLXCF)(TSX VENTURE:SLX), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today announced financial results for the second quarter ended June 30, 2005. All amounts in this press release are in Canadian dollars, and are the result of the use of U.S. GAAP. Peter Riehl, President and Chief Executive Officer of Stellar, commented, "The second quarter marked the fourth consecutive quarter of double-digit increases in year-over-year product sales. Canadian sales of NeoVisc(R) remained strong during the second quarter of 2005, while Canadian sales of Uracyst(R) resumed positive sales growth after experiencing a sales decline in the first quarter of 2005."

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050811005119&newsLang=en)